South Africa: World's Largest Research Funder Lifts Ban On South Africa
The United States National Institutes of Health (NIH) has lifted its 18-month ban on funding research in South Africa, a decision that had severely impacted HIV and TB studies and led to retrenchments. The move follows extensive negotiations and is expected to revitalize …
Intelligence analysis by Gemini 2.5 Flash
The NIH's decision to halt funding in January 2025 created a significant crisis for South Africa's globally recognized HIV and TB research, forcing many clinical trials to stop and researchers to be laid off. The recent lifting of this ban, confirmed by an internal memo, signals a potential return to vital scientific collaborations that have historically shaped global health policies.
Imagine a big club that helps scientists find cures for diseases. For a year and a half, this club stopped giving money to scientists in South Africa, which made it hard for them to work on important diseases like HIV and TB. Now, the club has decided to give money again, which is like turning the lights back on in the lab so they can continue their vital work.
Analysis
The recent decision by the United States National Institutes of Health (NIH) to lift its 18-month funding ban on South Africa marks a pivotal moment for global health research, particularly in the fight against HIV and tuberculosis. The ban, initiated in January 2025, had plunged South Africa's renowned biomedical research sector into crisis, halting numerous clinical trials and forcing the retrenchment of many dedicated researchers. This move underscores the profound interdependence of international scientific collaboration, especially given South Africa's historical role as a co-funder and a major contributor to HIV science, rather than merely a recipient of aid. The impact of the ban was far-reaching, affecting not only NIH grants but also US Agency for International Development (USAID) aid, disrupting decades of investment in research infrastructure and expertise.
National Institutes of Health
The NIH's reversal of its stop-work order, confirmed by an internal memo dated August 17, comes after a year of intense negotiations led by the South African Medical Research Council (SAMRC). This decision is a testament to the critical importance of South Africa's scientific contributions, which have historically shaped global health policies and revolutionized the prevention, diagnosis, treatment, and care of TB and HIV worldwide. The memo explicitly distinguishes NIH grants from traditional foreign aid, emphasizing their role in supporting "meritorious research projects." This clarification highlights the mutual benefit derived from these collaborations, acknowledging that advancements made in South Africa have significant implications for global health, including within the United States.
The ban had a devastating effect on institutions like the Desmond Tutu HIV Centre, which had to lay off staff due to its heavy reliance on NIH funding. The hiatus in receiving research protocols from US networks such as Advancing Clinical Therapeutics Globally (ACTG) and HIV Vaccine Trials Network (HVTN) created uncertainty for ongoing and future clinical trials. While the lifting of the ban brings renewed optimism, the full extent of its practical implications remains to be seen, especially given reported internal layoffs and budget constraints within the NIH itself.
South African Medical Research Council
The SAMRC played a crucial role in advocating for the lifting of the ban, engaging in 12 months of negotiations with the NIH. Ntobeko Ntusi, president and CEO of the SAMRC, emphasized South Africa's unique position as a co-funder of biomedical research with the NIH, rather than just a recipient, underscoring the bidirectional nature of the scientific partnership. This proactive stance by the SAMRC highlights South Africa's commitment to global health and its capacity to contribute significantly to scientific progress.
In response to the funding cuts, the SAMRC also took decisive action to mitigate the damage, announcing in August 2025 that it had raised approximately R600-million in rescue funds. This substantial amount included R400-million from the National Treasury, R100-million from the Gates Foundation, R100-million from the Wellcome Trust, and R14.4-million from the ELMA Foundation. These funds provided a crucial lifeline to affected research projects and groups, demonstrating a strong national and international commitment to sustaining South Africa's research capabilities during the funding hiatus.
Fogarty International Center
Despite the overall positive development of the ban being lifted, a significant caveat remains regarding the Fogarty International Center. The NIH memo explicitly states that the Fogarty International Center is "no longer supporting research training and career development applications from South Africa." This decision is attributed to South Africa's classification as an upper-middle-income country. This particular aspect of the NIH's policy raises concerns among researchers.
Landon Myer of UCT's School of Public Health noted that the Fogarty training had historically invested heavily in South African scientists over decades, which directly contributed to numerous "scientific accomplishments" within the country. The withdrawal of this specific training support, even as research funding resumes, could potentially undermine long-term capacity building and the development of future generations of South African scientists. While the immediate research funding is restored, the cessation of dedicated training support represents a nuanced challenge for the sustained growth and independence of South Africa's biomedical research ecosystem.
Key points
- The US National Institutes of Health (NIH) lifted its 18-month funding ban on South Africa.
- The ban had severely impacted HIV and TB research, leading to halted trials and retrenchments.
- South African scientists have been crucial to major global advances in HIV science, largely NIH-funded.
- The South African Medical Research Council (SAMRC) negotiated for 12 months to reverse the ban and raised R600-million in rescue funds.
- The NIH's Fogarty International Center will no longer support research training in South Africa due to its upper-middle-income status.
The lifting of the ban promises a resurgence of critical HIV and TB research in South Africa, allowing scientists to resume halted trials and re-engage in global collaborations. This renewed funding could lead to significant advancements in understanding and combating these diseases, benefiting both local populations and global health efforts.
Despite the lifted ban, some experts remain cautiously optimistic, noting that the situation might not fully return to its previous state due to internal NIH layoffs and budget limitations. Furthermore, the Fogarty International Center's continued withdrawal of support for research training in South Africa, due to its upper-middle-income status, could hinder long-term capacity building for local scientists.
